A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a single arm, multi-center study to evaluate the efficacy and safety of orelabrutinib
for Chronic lymphocytic lymphoma（CLL)/small lymphocytic lymphoma (SLL) patients who are
slowly responding to Ibrutinib switched to Orelabrutinib.